Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in Sri Lanka
…, D Guruge, D Jayathilaka, B Gunasekara… - MedRxiv, 2021 - medrxiv.org
Background As there are limited data of the immunogenicity of the Sinopharm/BBIBP-CorV
in different populations, antibody responses against different SARS-CoV-2 variants of …
in different populations, antibody responses against different SARS-CoV-2 variants of …
[HTML][HTML] Comparison of two assays to detect IgG antibodies to the receptor binding domain of SARS‑CoV‑2 as a surrogate marker for assessing neutralizing antibodies …
A Kamaladasa, B Gunasekara, C Jeewandara… - International Journal of …, 2021 - Elsevier
Background Neutralizing antibodies (NAbs) are important for protection against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection. In this study, two assays …
respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection. In this study, two assays …
[HTML][HTML] Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac)
…, ST Ramu, A Kamaladasa, B Gunasekara… - Scientific Reports, 2022 - nature.com
As the first dose of Gam-COVID-Vac, is currently used as a single dose vaccine in some
countries, we investigated the immunogenicity of this at 4 weeks (327 naïve individuals). 88.7% …
countries, we investigated the immunogenicity of this at 4 weeks (327 naïve individuals). 88.7% …
[HTML][HTML] Antibody responses to Sinopharm/BBIBP-CorV in pregnant mothers in Sri Lanka
…, IS Aberathna, B Gunasekara… - PLOS global public …, 2022 - journals.plos.org
Background There are limited data regarding the safety and immunogenicity of the
Sinopharm/BBIBP-CorV vaccine in pregnancy. Therefore, we sought to investigate the antibody …
Sinopharm/BBIBP-CorV vaccine in pregnancy. Therefore, we sought to investigate the antibody …
Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac)
…, S Tanussiya, A Kamaladasa, B Gunasekara… - 2021 - researchsquare.com
As the first dose of Gam-COVID-Vac, is currently used as a single dose vaccine in some
countries, we investigated the immunogenicity of this at 4 weeks (327 naïve individuals). 88.7% …
countries, we investigated the immunogenicity of this at 4 weeks (327 naïve individuals). 88.7% …
[HTML][HTML] Seroprevalence of SARS-CoV-2 infection in the Colombo municipality region, Sri Lanka
Background: As the Municipality Council area in Colombo (CMC) experienced the highest
number of cases until the end of January 2021, in Sri Lanka, we carried out a serosurvey prior …
number of cases until the end of January 2021, in Sri Lanka, we carried out a serosurvey prior …
Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals
C Jeewandara, IS Aberathna, PD Pushpakumara… - MedRxiv, 2021 - medrxiv.org
Background To determine the kinetics and persistence of immune responses following the
Sinopharm/BBIBP-CorV, we investigated immune responses in a cohort of Sri Lankan …
Sinopharm/BBIBP-CorV, we investigated immune responses in a cohort of Sri Lankan …
Immune responses to a single dose of the AZD1222/Covishield vaccine at 16 weeks in individuals in Sri Lanka
C Jeewandara, D Guruge… - The Journal of …, 2021 - journals.aai.org
Due to limited access to vaccines, many countries have only administered a single dose of
the AZD1222, whereas the dosage intervals have increased≥ 4 wk. We sought to investigate …
the AZD1222, whereas the dosage intervals have increased≥ 4 wk. We sought to investigate …
[CITATION][C] Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in Sri Lanka (preprint)
…, D Guruge, D Jayathilaka, B Gunasekara… - 2021
[CITATION][C] Seroprevalence of SARS-CoV-2 infection in the Colombo Municipality region, Sri Lanka (preprint)
…, IS Aberathna, S Danasekara, B Gunasekara… - 2021